Article: Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report

We present the first case of simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death 1 therapy. A 48-year-old man with parotid gland adenocarcinoma and lung metastasis had received five courses of nivolumab. Fourteen days after administration of the sixth course, his casual plasma glucose and hemoglobin A1c levels were 379 mg/dL and 7.2%, respectively. Furthermore, thyrotoxicosis was detected with a blood test. Serum total ketone body and thyroid-stimulating hormone receptor antibody levels increased, and serum C-peptide level decreased to 0.01 ng/mL thereafter. Thus, we concluded that he simultaneously developed anti-programmed cell death 1 therapy-associated type 1 diabetes and Graves' disease. Among Japanese patients with autoimmune polyglandular syndrome type III, the frequency of human leukocyte antigen-DRB1*04:05 is higher in those with both type 1 diabetes and Graves' disease. Our case had human leukocyte antigen-DRB1*04:05, which might be associated with the simultaneous development of the two diseases.

Citing Articles

Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature.

Pan Q, Li P Front Immunol. 2024; 15:1366335.

PMID: 38707904 PMC: 11067522. DOI: 10.3389/fimmu.2024.1366335.

A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab.

Kidawara Y, Kadoya M, Kakutani-Hatayama M, Koyama H Case Rep Endocrinol. 2024; 2024:4662803.

PMID: 38559614 PMC: 10980546. DOI: 10.1155/2024/4662803.

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review.

Profili N, Castelli R, Gidaro A, Merella A, Manetti R, Palmieri G J Clin Med. 2023; 12(15).

PMID: 37568563 PMC: 10419837. DOI: 10.3390/jcm12155161.

Endocrine side effects of immune checkpoint inhibitors.

Cardona Z, Sosman J, Chandra S, Huang W Front Endocrinol (Lausanne). 2023; 14:1157805.

PMID: 37251665 PMC: 10210589. DOI: 10.3389/fendo.2023.1157805.

Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms.

de Filette J, Andre S, De Mey L, Aspeslagh S, Karmali R, Van der Auwera B BMC Endocr Disord. 2022; 22(1):291.

PMID: 36419114 PMC: 9682778. DOI: 10.1186/s12902-022-01190-5.

References

1.

Kurihara S, Oikawa Y, Nakajima R, Satomura A, Tanaka R, Kagamu H . Simultaneous development of Graves' disease and type 1 diabetes during anti-programmed cell death-1 therapy: A case report. J Diabetes Investig. 2020; 11(4):1006-1009. PMC: 7378416. DOI: 10.1111/jdi.13212. View

2.

Byun D, Wolchok J, Rosenberg L, Girotra M . Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017; 13(4):195-207. PMC: 5629093. DOI: 10.1038/nrendo.2016.205. View

3.

Rydzewska M, Jaromin M, Pasierowska I, Stozek K, Bossowski A . Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res. 2018; 11:2. PMC: 5812228. DOI: 10.1186/s13044-018-0046-9. View

4.

Ikegami H, Awata T, Kawasaki E, Kobayashi T, Maruyama T, Nakanishi K . The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. J Clin Endocrinol Metab. 2005; 91(3):1087-92. DOI: 10.1210/jc.2005-1407. View

5.

Hashimoto K, Maruyama H, Nishiyama M, Asaba K, Ikeda Y, Takao T . Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. Horm Res. 2005; 64(5):253-60. DOI: 10.1159/000089293. View

6.

Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T . Class II HLA genotype in fulminant type 1 diabetes: A nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2014; 3(1):62-9. PMC: 4014934. DOI: 10.1111/j.2040-1124.2011.00139.x. View

7.

Delivanis D, Gustafson M, Bornschlegl S, Merten M, Kottschade L, Withers S . Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab. 2017; 102(8):2770-2780. PMC: 5546861. DOI: 10.1210/jc.2017-00448. View

8.

Alvarez-Sierra D, Marin-Sanchez A, Ruiz-Blazquez P, de Jesus Gil C, Iglesias-Felip C, Gonzalez O . Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun. 2019; 103:102285. DOI: 10.1016/j.jaut.2019.05.013. View

9.

Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim Y, Nomura M . Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One. 2019; 14(5):e0216954. PMC: 6516638. DOI: 10.1371/journal.pone.0216954. View

10.

de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B . Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab. 2016; 101(11):4431-4439. PMC: 5095250. DOI: 10.1210/jc.2016-2300. View

Simultaneous Development of Graves' Disease and Type 1 Diabetes During Anti-programmed Cell Death-1 Therapy: A Case Report